A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib (AV-951) to Sorafenib in Subjects With Advanced Renal Cell Carcinoma (TIVO-1).
Phase of Trial: Phase III
Latest Information Update: 15 Nov 2017
At a glance
- Drugs Tivozanib (Primary) ; Sorafenib
- Indications Renal cell carcinoma
- Focus Registrational; Therapeutic Use
- Acronyms TIVO-1
- Sponsors AVEO Oncology
- 15 Nov 2017 According to an AVEO Oncology media release, company plans to file for FDA approval, once results from Tivo-3 trial are available.
- 05 Oct 2017 According to an Aveo Oncology media release, the results from TIVO-3 and the TIVO-1 trial will support regulatory approval of tivozanib in the U.S. as a first and third line treatment for RCC
- 28 Aug 2017 Results published in an AVEO Oncology Media Release.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History